DualityBio tries to float again
The group expects to raise nearly $170m.
Head and neck cancer is next for evorpacept
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
BeiGene bows out of TIGIT
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
Enhertu could fill a gastric hole
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
